MicroRNAs as a Novel Player for Differentiation of Mesenchymal Stem Cells into Cardiomyocytes

Curr Stem Cell Res Ther. 2023;18(1):27-34. doi: 10.2174/1574888X17666220422094150.

Abstract

Cardiovascular disease (CVD) is defined as a class of disorders affecting the heart and blood vessels. Cardiomyocytes and endothelial cells play important roles in cardiac regeneration and heart repair. However, the proliferating capacity of cardiomyocytes is limited. To overcome this issue, mesenchymal stem cells (MSCs) have emerged as an alternative strategy for CVD therapy. MSCs can proliferate and differentiate (or trans-differentiate) into cardiomyocytes. Several in vitro and in vivo differentiation protocols have been used to obtain MSCs-derived cardiomyocytes. It was recently investigated that microRNAs (miRNAs) by targeting several signaling pathways, including STAT3, Wnt/β-catenin, Notch, and TBX5, play a crucial role in regulating cardiomyocytes' differentiation of MSCs. In this review, we focused on the role of miRNAs in the differentiation of MSCs into cardiomyocytes.

Keywords: Cardiovascular disease; MicroRNAs; cardiomyocytes; endothelial cells; mesenchymal stem cells; proliferating capacity.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases*
  • Cell Differentiation / genetics
  • Endothelial Cells
  • Humans
  • Mesenchymal Stem Cells*
  • MicroRNAs* / genetics
  • Myocytes, Cardiac

Substances

  • MicroRNAs